Browsing Tag

SciSparc Ltd

SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its…

Jason Junior Jun 30, 2022

TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central…

Health

SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum…

Jason Junior Jun 23, 2022

The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment TEL AVIV, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) ("Company" or…

Health

SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of…

Jason Junior Jun 15, 2022

JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company…

Newer Posts